Edition:
United States

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.39USD
12:04pm EDT
Change (% chg)

$-0.02 (-1.42%)
Prev Close
$1.41
Open
$1.40
Day's High
$1.42
Day's Low
$1.38
Volume
44,523
Avg. Vol
84,677
52-wk High
$1.85
52-wk Low
$1.04

Latest Key Developments (Source: Significant Developments)

Pluristem provides results from acute radiation syndrome preclinical study
Wednesday, 3 May 2017 07:00am EDT 

May 3 (Reuters) - Pluristem Therapeutics Inc :Pluristem therapeutics inc- announces promising results from non-human primate pilot study of plx-r18 in acute radiation syndrome.Pluristem-Plx-R18 cells did not increase leukocyte levels in non-irradiated nhps; all plx-treated groups showed improvements in survival rates versus untreated groups.Pluristem therapeutics inc- data will inform a pivotal trial that could support marketing authorization under fda's animal rule regulatory pathway.  Full Article

Pluristem appoints Erez Egozi as CFO
Wednesday, 29 Mar 2017 04:00pm EDT 

Pluristem Therapeutics Inc : Pluristem launches co-CEO structure and appoints new CFO . Pluristem Therapeutics Inc - Erez Egozi appointed as chief financial officer . Pluristem Therapeutics Inc - Yaky Yanay appointed co-chief executive officer to serve together with co-chief executive officer Zami Aberman .Pluristem Therapeutics Inc - Erez Egozi appointed as chief financial officer.  Full Article

Pluristem announces bought deal offering
Thursday, 19 Jan 2017 04:53pm EST 

Pluristem Therapeutics Inc : Pluristem announces bought deal offering . Pluristem Therapeutics Inc says to sell 8.2 million shares of common stock of company, at a price to public of US$1.225 per share .Pluristem Therapeutics - Use proceeds of offering for research, product development activities, clinical trial activities, investment in capital equipment.  Full Article

Pluristem completes patient enrollment in phase II trial in intermittent claudication
Thursday, 12 Jan 2017 06:00am EST 

Pluristem Therapeutics Inc : Pluristem completes patient enrollment in a large multinational phase II trial in intermittent claudication . Expect to report top line results in early 2018 for phase II IC trial .Pluristem's IC trial is evaluating safety and efficacy of PLX-PAD cells as compared to placebo.  Full Article

U.S. FDA clears Pluristem's Phase III study of PLX-PAD cells for treatment of critical limb ischemia
Tuesday, 10 Jan 2017 07:00am EST 

Pluristem Therapeutics Inc : Pluristem's Phase III study of PLX-PAD cells for the treatment of critical limb ischemia cleared by U.S. FDA .Pluristem expects to begin enrolling patients in its Phase III study in both U.S. and Europe during first half of 2017.  Full Article

Pluristem, Innovative Medical Management agree to extend time to execute definitive investment agreements
Friday, 23 Dec 2016 04:05am EST 

Pluristem Therapeutics Inc : Pluristem Therapeutics - parties plan to continue discussions until they receive further clarification about policies, expected during first half of 2017 .Pluristem and Innovative Medical Management Co., Ltd. Mutually agree to extend the time to execute the definitive investment agreements due to new Chinese monetary policy.  Full Article

Pluristem says PLX-R18 advances into 2nd cohort of dose selection study
Tuesday, 6 Dec 2016 07:00am EST 

Pluristem Therapeutics Inc - :Pluristem Therapeutics-PLX-R18 advances into 2nd cohort of dose selection study for treating acute radiation syndrome; data from 1st cohort study due in H1.  Full Article

Pluristem signs term sheet for $30 million equity investment agreement
Tuesday, 25 Oct 2016 06:40am EDT 

Pluristem Therapeutics Inc : Pluristem signs term sheet for $30 million equity investment agreement with a leading institutional life sciences fund . Pluristem therapeutics inc says funds to support late-stage pivotal trials for pluristem's cell therapies . Pluristem therapeutics inc - parties plan to enter into definitive agreements no later than december 26, 2016 . Pluristem therapeutics inc - shares will be sold at $1.77 . The shares will be subject to a lock up agreement for 6 months after closing of agreement . Parties plan to enter into definitive agreements no later than december 26, 2016 . Pluristem therapeutics - pluristem will issue to innovative medical approximately 4.4 million warrants to purchase shares of pluristem's common stock .Pluristem therapeutics-innovative medical will have one seat on co's board for as long as it holds at least 12.5% of co's issued and outstanding stock.  Full Article

Pluristem receives positive feedback from FDA, gears up for phase III trial of PLX-PAD in critical limb ischemia
Tuesday, 2 Aug 2016 07:30am EDT 

Pluristem Therapeutics Inc : Pluristem receives positive feedback from FDA and gears up for Phase III trial Of PLX-PAD in critical limb ischemia . Multinational study to be conducted in U.S. and Europe . Estimated trial enrollment of approximately 250 patients . Also moving CLI indication forward in Europe and Japan .Look forward to starting U.S. Phase III trial with our cell therapy for treatment of CLI by early 2017.  Full Article

Pluristem advances towards late-stage trial of PLX-PAD for recovery post hip surgery
Wednesday, 27 Jul 2016 07:00am EDT 

Pluristem: Pluristem advances towards multinational phase III trial of PLX-PAD to improve recovery following surgery for hip fracture . Has already submitted protocol to European medicines agency for a single pivotal study in this indication .Pluristem is planning to meet with FDA later this year to discuss phase iii protocol.  Full Article

More From Around the Web